PR Newswire BiotechOriginal article
NATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMI
Data ReadoutpositiveenVastPositive
AI Analysis
Summary
Vesalio announced positive results from the NATURE randomized controlled trial of enVast-assisted mechanical thrombectomy, which met its primary endpoint by showing reduced infarct size compared to conventional PCI in STEMI patients with large thrombus burden. Results were presented as late-breaking science at ESC Congress 2026.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
NATURE randomized controlled trial met primary endpoint, showing reduction in infarct size compared with conventional PCI in STEMI patients with large thrombus burden
Importance:7/10
Sentiment:
0.85
clinical trialcardiologySTEMImechanical thrombectomylate-breaking scienceESC Congress 2026
Read the original article
Published by PR Newswire Biotech on August 29, 2026 12:43 PM